Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Predicting R-CHOP Outcomes in DLBCL Patients
Blood; ePub 2016 Oct 19; Xu-Monette, Li, et al
The CD37 gene can predict rituximab-CHOP outcome in diffuse large B-cell lymphoma (DLBCL), particularly the germinal-center-B-cell–like variety, according to a study involving nearly 1,000 individuals.
Participants—all with DLBCL—had been treated with rituximab-CHOP (n=773) or CHOP chemotherapy (n=231). Investigators looked at clinical and biologic significance of CD37 expression. Among the results:
- CD37 loss (CD37-) was seen in 6 in every 10 patients; it predicted significantly lower survival rates in R-CHOP-treated patients.
- Conversely, CD37 positivity predicted better survival.
- Combining CD37-status and activated-B-cell–like cell-of-origin risk scores with the International Prognostic Index significantly improved prediction vs IPI alone.
- The same was true with IPI-plus-immunohistochemistry for CD37, Myc, and Bcl-2.
Citation:
Xu-Monette Z, Li L, Byrd J, et al. Assessment of CD37 B-cell antigen and cell-of-origin significantly improves risk prediction in diffuse large B-cell lymphoma. [Published online ahead of print October 19, 2016]. Blood. doi:10.1182/blood-2016-05-715094.